Related Experiment Video
Updated: Aug 30, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C
William L Thomas1, Fernando Ramos, Duane R Hospenthal
1wthomasmd@hotmail.com
Abstract:
Pegylated interferons have recently been approved for treatment of hepatitis C. The safety of these formulations is reported to be similar to that of non-pegylated interferon. We present two patients who experienced exacerbations of their liver disease following administration of pegylated interferon alfa-2b. Vigilant monitoring of patients treated with these new agents is recommended.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hypersensitivity Reactions: Cytolytic Reactions
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors